Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) CFO Bruce Jacobs sold 77,109 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total value of $8,864,450.64. Following the completion of the sale, the chief financial officer owned 244,883 shares of […]

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $545.80, for a total value of $5,185,100.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares […]

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) COO Jennifer Champoux sold 2,175 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $20.00, for a total value of $43,500.00. Following the transaction, the chief operating officer owned 62,371 shares in the […]

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) CFO Scott Burrows sold 15,000 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $87.13, for a total value of $1,306,950.00. Following the transaction, the chief financial officer directly owned 97,994 shares in the company, […]

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) insider Neil Gregory Almstead sold 5,323 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $85.03, for a total value of $452,614.69. Following the completion of the sale, the insider owned 60,137 shares in the […]

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $540.15, for a total transaction of $5,401,500.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares […]

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $537.74, for a total transaction of $5,108,530.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares […]